Clorox (NYSE:CLX) Given New $112.00 Price Target at Barclays

Key Points

• Barclays has lowered Clorox's price target from $118.00 to $112.00, maintaining an "underweight" rating, indicating a potential downside of 8.55% from the current stock price.
• Clorox's quarterly earnings exceeded expectations, with an EPS of $2.87, beating the consensus estimate by $0.63 and showing a revenue increase of 4.5% compared to the previous year.
• The stock has received mixed ratings, with one "buy," eight "hold," and two "sell" ratings, leading to an average price target of $141.09 according to MarketBeat.com.

Clorox (NYSE:CLX - Get Free Report) had its target price decreased by research analysts at Barclays from $118.00 to $112.00 in a report released on Tuesday,MarketScreener reports. The brokerage presently has an "underweight" rating on the stock. Barclays's target price indicates a potential downside of 8.55% from the stock's previous close.

Other analysts have also recently issued reports about the company. Citigroup restated a "neutral" rating and issued a $135.00 price target (down from $140.00) on shares of Clorox in a research note on Tuesday, July 15th. UBS Group cut their price target on Clorox from $150.00 to $134.00 and set a "neutral" rating on the stock in a research note on Thursday, July 17th. JPMorgan Chase & Co. lifted their target price on Clorox from $133.00 to $135.00 and gave the stock a "neutral" rating in a research report on Monday, September 8th. Wells Fargo & Company cut their target price on Clorox from $130.00 to $125.00 and set an "equal weight" rating on the stock in a research report on Thursday, September 25th. Finally, Jefferies Financial Group cut their target price on Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. One research analyst has rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Reduce" and an average price target of $141.09.

Clorox Stock Down 0.4%

NYSE:CLX opened at $122.47 on Tuesday. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15. The stock's fifty day moving average is $123.46 and its two-hundred day moving average is $130.06. Clorox has a 52 week low of $116.53 and a 52 week high of $171.37. The stock has a market capitalization of $14.98 billion, a price-to-earnings ratio of 18.76, a price-to-earnings-growth ratio of 1.00 and a beta of 0.52.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.24 by $0.63. The business had revenue of $1.99 billion for the quarter, compared to analysts' expectations of $1.94 billion. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The company's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period last year, the firm earned $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Research analysts anticipate that Clorox will post 7.15 EPS for the current year.

Insider Transactions at Clorox

In related news, COO Eric H. Reynolds sold 15,041 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total value of $1,861,774.98. Following the sale, the chief operating officer owned 54,221 shares of the company's stock, valued at approximately $6,711,475.38. This represents a 21.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.57% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Clorox by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 15,845,496 shares of the company's stock worth $1,902,569,000 after buying an additional 272,420 shares during the period. Invesco Ltd. increased its position in shares of Clorox by 138.3% during the second quarter. Invesco Ltd. now owns 3,245,175 shares of the company's stock worth $389,648,000 after acquiring an additional 1,883,465 shares during the last quarter. Norges Bank purchased a new stake in shares of Clorox during the second quarter worth about $190,429,000. Northern Trust Corp increased its position in shares of Clorox by 2.3% during the first quarter. Northern Trust Corp now owns 1,528,920 shares of the company's stock worth $225,133,000 after acquiring an additional 34,655 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Clorox by 218.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,249,127 shares of the company's stock worth $149,983,000 after acquiring an additional 856,873 shares during the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.